Traws Pharma, Inc. Financing Cash Flow
Traws Pharma, Inc. (TRAW) reported Financing Cash Flow of $11.29 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-14
- Traws Pharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $9.39M, a 203.39% increase year-over-year.
- Traws Pharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $1.90M, a 14492.31% increase year-over-year.
- Traws Pharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $158.00K, a 99.21% decline year-over-year.
- Traws Pharma, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was -$62.00K.
- Traws Pharma, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $3.20M, a 90.57% decline from fiscal 2024.
- Traws Pharma, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $33.98M.
- Traws Pharma, Inc. net cash provided by (used in) financing activities for fiscal 2021 was $55.56M, a 187.03% increase from fiscal 2020.
- Traws Pharma, Inc. net cash provided by (used in) financing activities for fiscal 2020 was $19.36M, a 27.36% decline from fiscal 2019.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $11.29M 10-Q · filed 2026-08-14 | $11.45M derived: sum of 3 quarters · filed 2026-08-14 | $11.38M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $1.90M 10-Q · filed 2026-05-15 | $2.06M derived: sum of 2 quarters · filed 2026-05-15 | $1.99M derived: sum of 3 quarters · filed 2026-05-15 | $5.09M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $96.00K derived: sum of 2 quarters · filed 2026-04-15 | $3.19M derived: sum of 3 quarters · filed 2026-08-14 | $3.20M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$62.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $3.03M derived: sum of 2 quarters · filed 2026-08-14 | $3.05M 10-Q · filed 2025-11-13 | $23.02M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $3.11M 10-Q · filed 2026-08-14 | $23.09M derived: sum of 3 quarters · filed 2026-08-14 | $23.09M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $13.00K 10-Q · filed 2026-05-15 | $19.99M derived: sum of 2 quarters · filed 2026-05-15 | $19.99M derived: sum of 3 quarters · filed 2026-05-15 | |
| 2024-12-31 | $19.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | $19.98M derived: sum of 2 quarters · filed 2026-04-15 | $33.98M 10-K · filed 2026-04-15 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $14.00M 10-Q · filed 2025-11-13 | ||
| 2024-06-30 | $14.00M 10-Q · filed 2025-08-14 | |||
| 2021-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $19.91M derived: sum of 2 quarters · filed 2023-03-30 | $19.92M derived: sum of 3 quarters · filed 2023-03-30 | $55.56M 10-K · filed 2023-03-30 |
| 2021-09-30 | $19.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $19.95M derived: sum of 2 quarters · filed 2022-11-14 | $55.59M 10-Q · filed 2022-11-14 | $55.87M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $35.65M 10-Q · filed 2022-08-15 | $35.93M derived: sum of 3 quarters · filed 2022-08-15 | $38.65M derived: sum of 4 quarters · filed 2022-08-15 |
| 2021-03-31 | $35.64M 10-Q · filed 2022-05-13 | $35.92M derived: sum of 2 quarters · filed 2022-05-13 | $38.64M derived: sum of 3 quarters · filed 2022-05-13 | $40.22M derived: sum of 4 quarters · filed 2022-05-13 |
| 2020-12-31 | $279.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $3.00M derived: sum of 2 quarters · filed 2022-03-21 | $4.58M derived: sum of 3 quarters · filed 2022-03-21 | $19.36M 10-K · filed 2022-03-21 |
| 2020-09-30 | $2.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $4.30M derived: sum of 2 quarters · filed 2021-11-15 | $19.08M 10-Q · filed 2021-11-15 | $42.33M derived: sum of 4 quarters · filed 2021-11-15 |
| 2020-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $16.36M 10-Q · filed 2021-08-16 | $39.62M derived: sum of 3 quarters · filed 2021-08-16 | $42.58M derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $14.78M 10-Q · filed 2021-05-17 | $38.03M derived: sum of 2 quarters · filed 2021-05-17 | $41.00M derived: sum of 3 quarters · filed 2021-05-17 | $41.39M derived: sum of 4 quarters · filed 2021-05-17 |
| 2019-12-31 | $23.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $26.22M derived: sum of 2 quarters · filed 2021-03-18 | $26.61M derived: sum of 3 quarters · filed 2021-03-18 | $26.65M 10-K · filed 2021-03-18 |
| 2019-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $3.36M derived: sum of 2 quarters · filed 2020-11-16 | $3.39M 10-Q · filed 2020-11-16 | $3.39M derived: sum of 4 quarters · filed 2020-11-16 |
| 2019-06-30 | $391.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-12 | $424.00K 10-Q · filed 2020-08-12 | $424.00K derived: sum of 3 quarters · filed 2020-08-12 | $424.00K derived: sum of 4 quarters · filed 2020-08-12 |
| 2019-03-31 | $33.00K 10-Q · filed 2020-05-15 | $33.00K derived: sum of 2 quarters · filed 2020-05-15 | $33.00K derived: sum of 3 quarters · filed 2020-05-15 | $26.95M derived: sum of 4 quarters · filed 2020-05-15 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-27 | $0.00 derived: sum of 2 quarters · filed 2020-03-27 | $26.92M derived: sum of 3 quarters · filed 2020-03-27 | $35.66M 10-K · filed 2020-03-27 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $26.92M derived: sum of 2 quarters · filed 2019-11-12 | $35.66M 10-Q · filed 2019-11-12 | $36.70M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $26.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-14 | $35.66M 10-Q · filed 2019-08-14 | $36.70M derived: sum of 3 quarters · filed 2019-08-14 | $36.70M derived: sum of 4 quarters · filed 2019-08-14 |
| 2018-03-31 | $8.74M 10-Q · filed 2019-05-15 | $9.78M derived: sum of 2 quarters · filed 2019-05-15 | $9.78M derived: sum of 3 quarters · filed 2019-05-15 | $15.06M derived: sum of 4 quarters · filed 2019-05-15 |
| 2017-12-31 | $1.04M derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01 | $1.04M derived: sum of 2 quarters · filed 2019-04-01 | $6.32M derived: sum of 3 quarters · filed 2019-04-01 | $6.36M 10-K · filed 2019-04-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-14 | $5.28M derived: sum of 2 quarters · filed 2018-11-14 | $5.32M 10-Q · filed 2018-11-14 | $5.32M derived: sum of 4 quarters · filed 2018-11-14 |
| 2017-06-30 | $5.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-14 | $5.32M 10-Q · filed 2018-08-14 | $5.32M derived: sum of 3 quarters · filed 2018-08-14 | $21.13M derived: sum of 4 quarters · filed 2018-08-14 |
| 2017-03-31 | $40.00K 10-Q · filed 2018-05-15 | $39.00K derived: sum of 2 quarters · filed 2018-05-15 | $15.85M derived: sum of 3 quarters · filed 2018-05-15 | |
| 2016-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $15.81M derived: sum of 2 quarters · filed 2018-03-16 | $17.42M 10-K · filed 2018-03-16 | |
| 2016-09-30 | $15.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $17.42M 10-Q · filed 2017-11-09 | ||
| 2016-06-30 | $1.61M 10-Q · filed 2017-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |